Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X:
“Hot Off The Press
Big News Release by Summit Therapeutics in time with ASCO 25.
Results from the HARMONi Phase III global trial evaluating:
Ivonescimab + Chemo vs Chemo in patients with advanced EGFR+ NSCLC after progression on 3rd gen TKI:Statistically significant and clinically meaningful Improvement in progression-free survival.
PFS HR: 0.52
OS positive trend: HR 0.79″
Read more about HARMONi Study.
More posts featuring Rami Manochakian on OncoDaily.